Rezera Inc. S-1IPO prospectus

Executive Summary

Rezera develops oral anti-inflammatory drugs for cardiovascular and neuroinflammatory diseases; it has no approved products or revenue. Its lead candidate, ruvonoflast, is heading toward a planned Phase 3 peripheral artery disease trial despite never having been tested in that patient population. H1 2026 net loss reached $(25.5)M as development spending accelerated, while subsequent financing supports operations only into January 2027. The IPO is unpriced, leaving its valuation and buyers’ ownership stake undetermined; investors are financing the leap from encouraging inflammatory biomarkers to demonstrated patient benefit.

Business Model and Growth Drivers

Rezera owns worldwide rights to ruvonoflast and trabzanoflast, retaining commercialization upside but bearing development costs. Ruvonoflast inhibits NLRP3, an upstream inflammatory pathway, and is designed to penetrate tissues and the brain. Management proposes first treating peripheral artery disease, where inflammation persists despite standard cardiovascular treatment, then expanding into broader atherosclerotic cardiovascular disease. Trabzanoflast has completed Phase 1 and is intended for Phase 2 neuroinflammatory studies; clinical benefit remains unproven.

• Clinical evidence: In the 176-person RESOLVE-1 trial, ruvonoflast significantly reduced high-sensitivity C-reactive protein, an inflammation marker, but missed its co-primary weight-loss endpoint. Highlighted reductions of 56%–63% came from a post-hoc subgroup selected for inflammation and adherence—not the entire randomized population. Five completed trials support further testing, not established benefit in peripheral artery disease.
• Commercial ambition: Management estimates a ≈$5B peripheral artery disease market and proposes launching through ≈50 U.S. centers of excellence. These are company assumptions, not demonstrated demand; Rezera has no pharmaceutical sales infrastructure.
• Execution: With 21 full-time employees, Rezera outsources trials and manufacturing. Ruvonoflast drug substance and proprietary material currently depend on one supplier.
• Competitive position: Oral dosing and broad pathway inhibition could differentiate ruvonoflast, but competing NLRP3 programs include better-funded pharmaceutical companies. Its granted composition-of-matter patent family is expected to expire in July 2038, before possible extensions.

The Offering

• Size and valuation: This preliminary offering is unpriced, with share count and proceeds blank; implied market capitalization, buyer ownership and offering-price dilution therefore cannot be computed. The capitalization section’s adjusted pre-offering base is 146.8M shares.
• Potential dilution: Adding disclosed existing and subsequent options and warrants produces a computed 181.7M pre-offering fully diluted count. A conditional 3.08M-option award to Nicholas Clarke would increase it to 184.8M, before IPO shares, further chief executive anti-dilution grants and future plan awards.
• Distribution: Rezera is selling common shares and intends to list on Nasdaq as RZRA. Jefferies, TD Cowen and Cantor are joint bookrunners; Wedbush PacGrow is lead manager. Underwriters have a 30-day additional-share option.
• Uses: Proceeds would fund the proposed Phase 3 trial, commercial preparations, earlier programs and general operations. Management says available resources plus IPO proceeds will not fund the pipeline through approval.
• Capitalization bridge: Before the IPO, cash was $3.85M and equity was $(199)M. The filing’s pro forma presentation—not including IPO proceeds—raises cash to $34.0M after subsequent financing and equity to $16.8M after preferred-stock conversion and other adjustments. Net tangible assets, meaning assets less liabilities and excluded non-tangible items, become $15.1M, or $0.10 per share.
• Resale restrictions: Directors, executives and substantially all existing securityholders face 180-day post-prospectus lock-ups, subject to exceptions and waivers; their eventual release could materially expand tradable supply.

Key Financial Highlights

$M; historical figures. Balance-sheet amounts are period-end.

• Equity deficit: At 6/30/2026, $201M of convertible preferred stock sat outside stockholders’ equity, alongside a $211M accumulated deficit. Conversion moves preferred capital into common equity; accrued preferred dividends are waived at completion.
• Spending concentration: H1 2026 ruvonoflast R&D reached $13.9M, driven by trial-service costs and manufacturing work ahead of Phase 3.
• Cyber incident: FY2025 administration expense included a $2.00M fraudulent-transfer loss; H1 2026 included $0.389M of additional recovery income. Recoveries of previously recorded insurance receivables also benefited cash flow.
• Funding: Subsequent preferred financing and a $15.0M secured term loan extend runway into January 2027. Loan interest is at least 6.00%, with principal amortization scheduled from 7/1/2027 unless extended.

Governance and Control

• Voting: Listed common shares carry one vote each. Novo Holdings and Blue Owl held a combined 48.45% before the offering on the principal-stockholder section’s conversion basis, giving institutions substantial influence.
• Entrenchment: A staggered board, cause-only director removal requiring two-thirds approval and restrictions on stockholder action make replacing leadership harder.
• Incentives: Chief executive Geoffrey McDonough’s agreement targets ≈5% fully diluted ownership through additional options; the IPO is expected to trigger another anti-dilution obligation. The new equity plan permits annual reserve increases of up to 5%, creating recurring dilution potential.

Risk Assessment

• Going concern and controls: Management and the auditor identify substantial going-concern doubt, while financial-reporting material weaknesses require remediation.
• Clinical leap: Ruvonoflast’s biomarker results must translate into walking improvement in an untested patient population; regulators may require more than the proposed single pivotal trial.
• Financing gap: Runway ends before planned Phase 3 initiation, making further funding essential and potentially dilutive.
• Supply dependency: Failure of the sole ruvonoflast supplier could interrupt the lead program.
• Commercial uncertainty: The ≈$5B opportunity depends on approval, reimbursement and adoption, against competing therapies and an unbuilt sales organization.
• Personnel dependency: A small workforce’s reliance on specialized scientific and clinical staff makes departures potentially disruptive to development.

What to Watch

• RELIEVE-PAD execution: Management plans an ≈800-patient trial starting H1 2027 and reading out in 2028; later filings should establish regulatory agreement, enrollment and walking-distance benefit—or show delays and additional-study requirements.
• Trabzanoflast progression: Phase 1 is complete; Phase 2 initiation and patient evidence would establish a second opportunity, while continued early-stage status leaves dependence on ruvonoflast.
• Funding sufficiency: Runway currently reaches January 2027; IPO terms and subsequent cash use will show whether financing supports the trial or another raise intervenes.